Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
Document Type
Article
Publication Title
Leukemia & lymphoma
Abstract
The standard preparative regimen for autologous stem cell transplant (ASCT) in multiple myeloma (MM) is 200 mg/m
First Page
1315
Last Page
1321
DOI
10.1080/10428194.2023.2213366
Publication Date
1-1-2023
Recommended Citation
Sharma N, Benson E, Zhao Q, Nunnelee J, Cottini F, Elder P, Rosko A, Bumma N, Khan A, Umyarova E, Devarakonda S, Efebera YA, Benson DM. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma. Leuk Lymphoma. 2023 Jul-Aug;64(7):1315-1321. doi: 10.1080/10428194.2023.2213366. Epub 2023 May 18. PMID: 37199099.
COinS